ES2074719T3 - Derivados de nucleosido de pirimidina. - Google Patents

Derivados de nucleosido de pirimidina.

Info

Publication number
ES2074719T3
ES2074719T3 ES91911192T ES91911192T ES2074719T3 ES 2074719 T3 ES2074719 T3 ES 2074719T3 ES 91911192 T ES91911192 T ES 91911192T ES 91911192 T ES91911192 T ES 91911192T ES 2074719 T3 ES2074719 T3 ES 2074719T3
Authority
ES
Spain
Prior art keywords
pirimidine
nucleoside derivatives
hydroxy
hydrogen
represent
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES91911192T
Other languages
English (en)
Inventor
Akira Matsuda
Takuma Sasaki
Tohru Ueda
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sankyo Co Ltd
Original Assignee
Sankyo Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sankyo Co Ltd filed Critical Sankyo Co Ltd
Application granted granted Critical
Publication of ES2074719T3 publication Critical patent/ES2074719T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/06—Pyrimidine radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H23/00—Compounds containing boron, silicon, or a metal, e.g. chelates, vitamin B12

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

SE PRESENTA UN NUEVO DERIVADO NUCLEOSIDO DE LA PIRIMIDINA DE LA FORMULA (I) O (II) Y UNA SAL DEL MISMO, EN DONDE R1 REPRESENTA AMINO QUE PUEDE ESTAR SUBSTITUIDO CON HIDROXIDO O AZIL; R2 REPRESENTA HIDROGENO O ALQUIL C1-C4; R3 REPRESENTA HIDROGENO O HIDROXIDO; Y R4 Y R5 REPRESENTAN CADA UNA HIDROGENO O PUEDEN ESTAR COMBINADAS JUNTAS PARA REPRESENTAR -R6R6''SI-O-SIR7R7''-, EN DONDE R6, R6'', R7 Y R7'' REPRESENTAN CADA UNA ALQUIL INFERIOR. ESTE COMPUESTO TIENE UN EXCELENTE EFECTO ANTITUMORAL O SIRVE COMO PRODUCTO INTERMEDIO UTIL PARA LA SINTESIS DE DROGAS ANTITUMORALES.
ES91911192T 1990-06-15 1991-06-13 Derivados de nucleosido de pirimidina. Expired - Lifetime ES2074719T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP15668890 1990-06-15

Publications (1)

Publication Number Publication Date
ES2074719T3 true ES2074719T3 (es) 1995-09-16

Family

ID=15633157

Family Applications (1)

Application Number Title Priority Date Filing Date
ES91911192T Expired - Lifetime ES2074719T3 (es) 1990-06-15 1991-06-13 Derivados de nucleosido de pirimidina.

Country Status (13)

Country Link
US (2) US5616567A (es)
EP (1) EP0535231B1 (es)
JP (1) JP2559917B2 (es)
KR (1) KR970011306B1 (es)
AT (1) ATE122041T1 (es)
CA (1) CA2085345C (es)
DE (1) DE69109482T2 (es)
DK (1) DK0535231T3 (es)
ES (1) ES2074719T3 (es)
HK (1) HK1005871A1 (es)
HU (1) HU218924B (es)
RU (1) RU2116306C1 (es)
WO (1) WO1991019713A1 (es)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FI105556B (fi) * 1991-09-30 2000-09-15 Sankyo Co Menetelmä lääkeaineina käyttökelpoisten pyrimidiiniukleosidijohdannaisten valmistamiseksi, joilla on kasvaimen vastaista vaikutusta
KR20030036189A (ko) * 2000-05-26 2003-05-09 이데닉스(케이만)리미티드 플라비바이러스 및 페스티바이러스의 치료방법 및 조성물
MY142304A (en) * 2005-01-31 2010-11-15 Taiho Pharmaceutical Co Ltd Novel pyrimidine nucleoside compound or salt thereof
GB0523041D0 (en) * 2005-11-11 2005-12-21 Cyclacel Ltd Combination
WO2008010571A1 (fr) 2006-07-21 2008-01-24 Taiho Pharmaceutical Co., Ltd. Composé nucléosidique de 2'cyanopyrimidine
GB0625283D0 (en) 2006-12-19 2007-01-24 Cyclacel Ltd Combination
RU2488591C2 (ru) * 2007-09-26 2013-07-27 Маунт Синай Скул Оф Медсин Аналоги азацитидина и их применение
US8124593B2 (en) 2007-11-05 2012-02-28 Cyclacel Limited Methods of treatment using sapacitabine
US7863255B2 (en) * 2008-04-29 2011-01-04 Taiho Pharmaceutical Co., Ltd. Methods of administering antitumor agent comprising deoxycytidine derivative
GB0808359D0 (en) * 2008-05-08 2008-06-18 Cyclacel Ltd Process
GB0808357D0 (en) * 2008-05-08 2008-06-18 Cyclacel Ltd Process
CA2725295C (en) 2008-06-09 2016-11-08 Cyclacel Limited Combination of sapacitabine (cndac) and dna methyltransferase inhibitors such as decitabine and procaine
DK2431376T4 (da) * 2009-05-15 2024-02-26 Delta Fly Pharma Inc Ny stabilt krystal af 1-(2'-cyano-2'-deoxy-ß-D-arabinofuranosyl)cytosinmonohydrochlorid
EP2696878B1 (en) 2011-04-14 2019-07-10 Cyclacel Limited Dosage regimen for sapacitabine and decitabine in combination for treating acute myeloid leukemia
CN104114568B (zh) 2011-12-22 2017-09-01 艾丽奥斯生物制药有限公司 取代的核苷、核苷酸及其类似物
USRE48171E1 (en) 2012-03-21 2020-08-25 Janssen Biopharma, Inc. Substituted nucleosides, nucleotides and analogs thereof
US9441007B2 (en) 2012-03-21 2016-09-13 Alios Biopharma, Inc. Substituted nucleosides, nucleotides and analogs thereof
JP6286421B2 (ja) 2012-05-15 2018-02-28 サイクラセル リミテッド サパシタビン及びセリシクリブの投与レジメン
WO2019081951A1 (en) 2017-10-27 2019-05-02 Cyclacel Limited DOSAGE REGIME
US11957701B2 (en) 2020-07-17 2024-04-16 Delta-Fly Pharma, Inc. Therapy and new therapeutic agent for blood cancer

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2007094A6 (es) * 1987-07-29 1989-06-01 Consejo Superior Investigacion Procedimiento para la preparacion de 3 -c- ciano-2,3 -didesoxinucleosido.

Also Published As

Publication number Publication date
KR970011306B1 (ko) 1997-07-09
EP0535231A4 (en) 1993-06-30
CA2085345C (en) 2001-08-07
CA2085345A1 (en) 1991-12-16
KR930700485A (ko) 1993-03-15
JPH04235182A (ja) 1992-08-24
HU218924B (hu) 2000-12-28
JP2559917B2 (ja) 1996-12-04
DE69109482T2 (de) 1996-02-15
US5616567A (en) 1997-04-01
RU2116306C1 (ru) 1998-07-27
DK0535231T3 (da) 1995-08-21
HUT62582A (en) 1993-05-28
HK1005871A1 (en) 1999-01-29
US5654420A (en) 1997-08-05
DE69109482D1 (en) 1995-06-08
HU9203967D0 (en) 1993-03-29
EP0535231A1 (en) 1993-04-07
ATE122041T1 (de) 1995-05-15
WO1991019713A1 (en) 1991-12-26
EP0535231B1 (en) 1995-05-03

Similar Documents

Publication Publication Date Title
ES2074719T3 (es) Derivados de nucleosido de pirimidina.
DE69434136D1 (de) Dolastatin-derivate
DE69840296D1 (de) Phenylethylenamin-derivate
PT747389E (pt) Derivados de nucleosido 3'-substituidos
DE3851179D1 (de) Oxetanocin.
FI952101A0 (fi) Merkaptanfoerening
MX9101232A (es) Derivados de benceno,piridina y pirimidina
ES2083625T3 (es) Derivados de n-feniltiourea y uso farmaceutico de los mismos.
ES2169220T3 (es) Derivados de vitamina d3 con sustituyentes en la posicion 2.
FI940011A (fi) Mono- ja bis-alkyyliaminoantrasykliinit
ES2096572T3 (es) Nuevos derivados de glucosidos de antraciclina y procedimiento para su preparacion.
ATE90685T1 (de) Disaccharidderivate.
NO904187D0 (no) Benzanilider.
ES2092714T3 (es) Derivados de indol.
IL166484A0 (en) Myriaporone derivatives
DE69231244D1 (de) Pyrazolothiazolopyrimidin-derivate

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 535231

Country of ref document: ES